Genta: FDA Favors Clinical Trial For Leukemia Drug Genasense
06 Marzo 2009 - 6:36PM
Noticias Dow Jones
DOW JONES NEWSWIRES
Genta Inc. (GNTA) said the Food and Drug Administration has
recommended a clinical trial for its cancer drug Genasense.
The FDA's Center for Drug Evaluation and Research ruled that
available data are not adequate to support approval of the
treatment for patients with chronic lymphocytic leukemia.
The biopharmaceutical company's chief medical officer, Dr.
Loretta M. Itri, said the company would discuss the matter with
clinical and regulatory authorities before deciding its next
steps.
-By Kathy Shwiff, Dow Jones Newswires; 201-938-5975;
Kathy.Shwiff@dowjones.com